Showing results (1221-1230 of 1,308) with videos related to
Sort By:
Pageof 131
Nature|May 25, 2012
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrityUrsula Fünfschilling, Lotti M Supplie, Don Mahad, et al.NPJ Vaccines|December 4, 2025
Polyvalent mRNA vaccine targeting outer surface protein C affords multi-strain protection against Lyme diseaseAnnabelle Pfeifle, Casey Lansdell, Wanyue Zhang, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 14, 2024
Education, employment, and income among people living with cystic fibrosis across three decades - A matched cohort study using Danish health registriesCamilla Bjørn Jensen, Kristoffer Jarlov Jensen, Tacjana Pressler, et al.Plos One|July 21, 2017
Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adultsSusan P Buchbinder, Nicole A Grunenberg, Brittany J Sanchez, et al.Cancer Research|March 3, 2006
Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissuesShyra J Miller, Fatima Rangwala, Jon Williams, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2006
Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responsesFlorian Bihl, Nicole Frahm, Loriana Di Giammarino, et al.Geroscience|May 21, 2026
Impact of an online-guided physical activity intervention on cognition, resting-state brain connectivity, and the gut microbiome in healthy older adults-a randomized controlled trialSimon J Schrenk, Corinna Bang, Lena Best, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2007
Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitopeKeri L Schaubert, David A Price, Nicole Frahm, et al.The Journal of Clinical Investigation|October 2, 2014
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialPierre-Alexandre Bart, Yunda Huang, Shelly T Karuna, et al.Journal of Virology|January 1, 2009
HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognitionToshiyuki Miura, Mark A Brockman, Arne Schneidewind, et al.Pageof 131